What is albiglutide? Structure, research and status

Albiglutide is a GLP-1 receptor agonist made by joining two modified GLP-1 copies to human albumin. FDA licensed it as Tanzeum in 2014, and GSK later stopped selling it.

Complete guide9 min read

Key takeaway

Albiglutide is a 72,970-dalton protein: two copies of a modified GLP-1 fragment fused to human albumin. In Harmony Outcomes, 9,463 adults with type 2 diabetes and cardiovascular disease were followed for a median of 1.6 years. Major cardiovascular events occurred in 7% on albiglutide versus 9% on placebo. In HARMONY 7, it lowered HbA1c less than liraglutide.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“Albiglutide is no longer FDA-approved, because FDA lists the Tanzeum license as voluntarily revoked.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited5 in this article · 5 across 1 article on Albiglutide
Related productsIncretin analogs

Albiglutide was developed by GlaxoSmithKline (GSK) and licensed by FDA as Tanzeum on April 15, 2014. In July 2017, GSK announced it would end research, manufacturing and sales. A large outcomes trial then reported fewer major cardiovascular events than placebo. FDA's Purple Book now lists the Tanzeum license as voluntarily revoked.

Quick answer: Albiglutide is a GLP-1 receptor agonist built as an albumin fusion protein. Albiglutide is no longer FDA-approved, because FDA lists the Tanzeum license as voluntarily revoked. The European Commission withdrew Eperzan, its EU brand, in October 2018 for commercial reasons. GSK stated the decision was not related to efficacy or safety.

Vitrapep does not sell albiglutide; this page is a reference summary of published research and regulatory information.

What is albiglutide and how is it built?

Albiglutide is a lab-made analog of glucagon-like peptide-1 (GLP-1), a gut hormone released after meals (see what GLP-1 is). GSK developed it under the code GSK716155 [4].

The label describes two tandem copies of human GLP-1 fragment 7-36, fused to human albumin. In each copy, glycine replaces the natural alanine at position 8, which resists breakdown by the enzyme DPP-4 [1]. Yeast cells (Saccharomyces cerevisiae) engineered to express the protein produce it [1].

The European Medicines Agency's assessment adds detail. The first GLP-1 copy is joined to the second, which is joined to the start of albumin. Each copy shares 97% sequence homology with native GLP-1 (7-36). The protein is not glycosylated [5].

At 72,970 daltons, albiglutide is a protein with peptide segments (see peptide vs protein). GSK applied on January 14, 2013, under section 351 of the Public Health Service Act, the pathway for biological products [3]. A Federal Register notice dates the investigational application to January 15, 2006. It names Human Genome Sciences as the patent term restoration applicant [6].

Table 1

What is albiglutide and how is it built

PropertyAlbiglutide
ClassGLP-1 receptor agonist; recombinant albumin fusion protein [1]
StructureTwo tandem copies of GLP-1 (7-36) with glycine at position 8, fused to human albumin [1], [5]
Molecular weight72,970 daltons for the full protein [1]
PubChem recordCID 122173812 lists C148H223N39O46 and 3284.6 g/mol, matching one modified GLP-1 segment of 30 amino acids, not the full protein [4]
Elimination half-lifeAbout 5 days [1]
Development codeGSK716155 [4]
US approvalTanzeum, licensed April 15, 2014, as a new molecular entity (Drugs@FDA)
US status in 2026Marketing status discontinued; license listed as voluntarily revoked [13]
EU statusEperzan authorized March 2014; withdrawn October 29, 2018 (EMA)
Boxed warningRisk of thyroid C-cell tumors [1]

How does albiglutide work?

The label calls albiglutide a GLP-1 receptor agonist that augments glucose-dependent insulin secretion and slows gastric emptying [1]. FDA's review adds that native GLP-1 also inhibits glucagon release [3]. Vitrapep explains this signaling in how GLP-1 receptor agonists work.

According to the label, the albumin portion and DPP-4 resistance together extend the half-life. Proteolytic enzymes are expected to break the protein into small peptides and amino acids, likely along the pathway of native albumin [1].

An early single-blind, placebo-controlled study enrolled 39 healthy volunteers. The terminal half-life was 6 to 8 days. Headache was the most frequent drug-related adverse event, followed by constipation, flatulence and nausea [7]. In label pharmacology studies, albiglutide slowed gastric emptying and did not impair the glucagon response to low glucose [1].

What was albiglutide approved for?

Under label section 1, Tanzeum was an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes [1].

It was not recommended as first-line therapy, because the human relevance of rodent thyroid tumor findings was uncertain. It was not for type 1 diabetes and was not studied with mealtime insulin. Safety and effectiveness were not established under age 18 [1].

The label had no cardiovascular indication [1]. At approval, FDA required a REMS communication plan covering thyroid cancer and pancreatitis risks. It also required a pediatric study, a thyroid cancer registry of at least 15 years and a cardiovascular outcomes trial [2]. FDA ended the REMS requirement in December 2017 (REMS letter).

What did the key albiglutide trials show?

FDA's review covered eight phase 3 trials, with primary results at 26 to 104 weeks. Albiglutide lowered HbA1c more than sitagliptin in two trials and glimepiride in one. It was noninferior to insulin glargine and insulin lispro, and inferior to pioglitazone and liraglutide in one trial each [3].

HARMONY 3 (NCT00838903) ran 104 weeks in adults taking metformin. Albiglutide lowered HbA1c more than placebo (0.9 points), sitagliptin (0.4) and glimepiride (0.3). Weight changed by -1.21 kg versus +1.17 kg on glimepiride [8].

HARMONY 7 (NCT01128894) compared albiglutide with liraglutide. HbA1c fell 0.78 versus 0.99 points, missing the noninferiority margin. Injection-site reactions occurred in 12.9% versus 5.4%, and gastrointestinal events in 35.9% versus 49.0% [9]. See the liraglutide complete guide.

Harmony Outcomes (NCT02465515) enrolled adults aged 40 and older with type 2 diabetes and cardiovascular disease, at 610 sites in 28 countries. Its primary outcome combined cardiovascular death, heart attack and stroke. The last patient visit was March 12, 2018, after GSK's discontinuation decision [10], [12].

Table 2

What did the key albiglutide trials show

TrialPopulation and sizeDesign and lengthPrimary result
HARMONY 3, 2014 [8]1,012 adults with type 2 diabetes on metformin, in four groupsRandomized, double-blind, versus placebo, sitagliptin and glimepiride; 104 weeksHbA1c lower than all three comparators; P = 0.0033 or smaller
HARMONY 7, 2014 [9]841 adults with type 2 diabetes on oral drugsRandomized, open-label, versus liraglutide; 32 weeksDifference 0.21 points (95% CI, 0.08 to 0.34); noninferiority not shown
Harmony Outcomes, 2018 [10]9,463 adults with type 2 diabetes and cardiovascular diseaseDouble-blind, placebo-controlled; median 1.6 yearsEvents in 338 of 4,731 vs 428 of 4,732; hazard ratio 0.78 (95% CI, 0.68 to 0.90); superior
Type 1 diabetes phase 2, 2020 [11]67 adults with newly diagnosed type 1 diabetesRandomized 3:1, placebo-controlled, with insulin; 52 weeksNo appreciable effect on residual beta-cell function

GSK sponsored all four trials, according to their registry records. In Harmony Outcomes, acute pancreatitis occurred in 10 versus 7 patients. No one in either group developed medullary thyroid carcinoma [10].

What else was albiglutide studied for?

Type 1 diabetes. A phase 2 trial (NCT02284009) added albiglutide or placebo to insulin in newly diagnosed adults. Over 52 weeks, stimulated C-peptide, a marker of remaining insulin production, fell 0.13 nmol/L versus 0.16 nmol/L. Adverse events occurred in 82.0% versus 76.5% [11].

Heart failure. A 12-week placebo-controlled study (NCT01357850) enrolled 82 adults with reduced ejection fraction. Albiglutide did not improve ejection fraction or walking distance. Peak oxygen consumption rose modestly versus placebo (Lepore et al., 2016).

Children. A planned pediatric trial (NCT03015519) never enrolled anyone. The registry says it did not start because albiglutide would have left the market before the study ended.

On November 18, 2026, ClinicalTrials.gov listed no active interventional albiglutide trial. Vitrapep's guide on how to find a peptide clinical trial explains these registry statuses.

What side effects did the Tanzeum label list?

Boxed warning. The label warned of thyroid C-cell tumors. Rodent carcinogenicity could not be tested, because the animals quickly made drug-clearing antibodies. The warning relied on tumors seen with other GLP-1 receptor agonists. Across eight phase 3 trials, medullary thyroid carcinoma was diagnosed in one patient on Tanzeum and one on placebo [1].

Table 3

What side effects did the Tanzeum label list

Adverse reactionTanzeum, % (n=923)Placebo, % (n=468)
Upper respiratory tract infection14.213.0
Diarrhea13.110.5
Nausea11.19.6
Injection site reaction10.52.1
Cough6.96.2
Back pain6.75.8
Arthralgia6.66.4
Sinusitis6.25.8
Influenza5.23.2

Source: Tanzeum label, Table 1, four placebo-controlled trials with a mean exposure of 93 weeks [1]. Gastrointestinal complaints occurred in 39% versus 33%. All injection-site reaction types combined occurred in 18% versus 8% [1].

Pancreatitis and blood sugar. Pancreatitis judged likely related to therapy occurred in 6 of 2,365 patients (0.3%) on Tanzeum. It occurred in 0 of 468 on placebo and 2 of 2,062 (0.1%) on active comparators. Hypoglycemia was more frequent with a sulfonylurea or insulin [1].

Other findings. Pneumonia occurred in 1.8% versus 0.8% on all comparators, and atrial fibrillation in 1.0% versus 0.5% [1].

Allergy, kidneys and antibodies. Serious hypersensitivity reactions, including angioedema, were reported. A December 2017 update added postmarketing acute kidney injury, some cases requiring hemodialysis. In pooled trials, 116 of 2,098 patients (5.5%) developed anti-albiglutide antibodies; none neutralized the drug in a lab assay [1].

Eye warning. FDA's November 9, 2026, NAION labeling action lists 12 GLP-1 products, and Tanzeum is not among them (FDA). See Vitrapep's summary of FDA's GLP-1 eye-risk warning.

Why was albiglutide discontinued?

In July 2017, GSK announced its intention to cease further research, manufacturing and sales for albiglutide. In October 2018, GSK said it no longer marketed or distributed albiglutide and was exploring opportunities to divest it [12].

A June 2018 GSK letter to UK pharmacists said sales would end worldwide, with UK supplies stopping on July 1, 2018. It called the withdrawal one made "on commercial grounds only," not related to efficacy or safety (GSK letter).

EMA reports that GSK decided to permanently stop marketing Eperzan for commercial reasons. The European Commission withdrew the authorization at GSK's request on October 29, 2018 (EMA).

What is the regulatory status of albiglutide?

United States. Drugs@FDA lists Tanzeum with a discontinued marketing status. FDA's October 2026 Purple Book data list its licensure as "Voluntarily Revoked" [13]. The Purple Book lists no biosimilar naming Tanzeum as its reference product [13].

Compounding. FDA says biological products subject to licensure under section 351 are not eligible for compounding exemptions under sections 503A and 503B [14]. Albiglutide was licensed under that section [3].

Sport. The WADA 2026 Prohibited List does not name albiglutide or GLP-1 receptor agonists.

Research-labeled products. A research-use-only label does not make a product approved, legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

What is still unknown about albiglutide?

FDA's review noted that long primary endpoints left much missing or imputed data, especially at week 104. The imputation method may have biased the noninferiority comparisons [3].

The last Tanzeum label, revised in December 2017, predates the Harmony Outcomes results. Harmony Outcomes lasted a median of 1.6 years, so longer-term effects are unknown [10]. The approval letter scheduled the thyroid cancer registry to finish in December 2029 [2]. This page found no public source on whether it continued after the license ended.

Frequently asked questions

Is albiglutide a peptide?

It contains two modified GLP-1 peptide segments, but the whole molecule is a 72,970-dalton protein. FDA licensed it as a biological product.

Is Tanzeum still available in the US?

No. Drugs@FDA lists Tanzeum as discontinued, and FDA's Purple Book lists its license as voluntarily revoked.

Why did GSK stop selling albiglutide?

GSK and EMA describe the decision as commercial. A GSK letter to UK pharmacists said it was not related to efficacy or safety.

Did albiglutide lower cardiovascular events?

In Harmony Outcomes, cardiovascular death, heart attack or stroke occurred in 7% on albiglutide versus 9% on placebo. The hazard ratio was 0.78.

How did albiglutide compare with liraglutide?

In the 32-week HARMONY 7 trial, albiglutide lowered HbA1c less than liraglutide. It caused fewer gastrointestinal events but more injection-site reactions.

Is research-grade albiglutide FDA-approved?

No. No albiglutide product holds a current FDA license, and material sold for laboratory research is not an approved medicine.

What to know now

  • Albiglutide is a 72,970-dalton fusion of two modified GLP-1 copies and human albumin, licensed by FDA as Tanzeum in 2014.
  • Harmony Outcomes showed fewer major cardiovascular events than placebo, but results came after GSK's 2017 decision to stop selling it.
  • The US license is listed as voluntarily revoked, and the EU authorization was withdrawn in October 2018 for commercial reasons.

What we’re watching

  • Whether any company takes up albiglutide after GSK's 2018 statement that it was exploring a divestment.
  • Any FDA update on the thyroid cancer registry required at approval.
  • New analyses of Harmony Outcomes data, the largest albiglutide dataset.

More for endocrine & metabolism

All 49 compounds for endocrine & metabolism

Sources: U.S. Food and Drug Administration 2017; U.S. Food and Drug Administration 2014; U.S. Food and Drug Administration 2014; National Center for Biotechnology Information 2026; European Medicines Agency 2014; U.S. Food and Drug Administration 2016, Federal Register; Bush 2009, Diabetes, Obesity and Metabolism, 11; Ahrén 2014, Diabetes Care, 37; Pratley 2014, Lancet Diabetes & Endocrinology, 2; Hernandez 2018, Lancet, 392; Pozzilli 2020, Journal of Clinical Endocrinology & Metabolism, 105; GSK 2018; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2020. All 14 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2017). Tanzeum (albiglutide) for injection: prescribing information, revised December 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125431s020lbl.pdf
  2. U.S. Food and Drug Administration. (2014). Approval letter, BLA 125431 (Tanzeum). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125431Orig1s000ltr.pdf
  3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2014). Summary review, application 125431Orig1s000 (Tanzeum). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431Orig1s000SumR.pdf
  4. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 122173812, albiglutide. https://pubchem.ncbi.nlm.nih.gov/compound/122173812
  5. European Medicines Agency. (2014). Eperzan: European public assessment report (EMA/CHMP/705417/2013). https://www.ema.europa.eu/en/documents/assessment-report/eperzan-epar-public-assessment-report_en.pdf
  6. U.S. Food and Drug Administration. (2016). Determination of regulatory review period for purposes of patent extension; TANZEUM. Federal Register, FR Doc 2016-13797. https://www.federalregister.gov/documents/2016/06/10/2016-13797/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tanzeum
  7. Bush, M. A., Matthews, J. E., De Boever, E. H., et al. (2009). Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes, Obesity and Metabolism, 11(5), 498-505. https://doi.org/10.1111/j.1463-1326.2008.00992.x
  8. Ahrén, B., Johnson, S. L., Stewart, M., et al. (2014). HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care, 37(8), 2141-2148. https://doi.org/10.2337/dc14-0024
  9. Pratley, R. E., Nauck, M. A., Barnett, A. H., et al. (2014). Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes & Endocrinology, 2(4), 289-297. https://doi.org/10.1016/S2213-8587(13)70214-6
  10. Hernandez, A. F., Green, J. B., Janmohamed, S., et al. (2018). Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, 392(10157), 1519-1529. https://doi.org/10.1016/S0140-6736(18)32261-X
  11. Pozzilli, P., Bosi, E., Cirkel, D., et al. (2020). Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes. Journal of Clinical Endocrinology & Metabolism, 105(6), e2192. https://doi.org/10.1210/clinem/dgaa149
  12. GSK. (2018, October 2). Positive results from Harmony Outcomes study of albiglutide published in The Lancet [Press release]. https://www.gsk.com/en-gb/media/press-releases/positive-results-from-harmony-outcomes-study-of-albiglutide-published-in-the-lancet/
  13. U.S. Food and Drug Administration. (2026). Purple Book: database of licensed biological products, October 2026 data download. https://www.accessdata.fda.gov/drugsatfda_docs/PurpleBook/2026/purplebook-search-October-data-download.csv
  14. U.S. Food and Drug Administration. (2020). Notice to compounders: changes that affect compounding as of March 23, 2020. https://www.fda.gov/drugs/human-drug-compounding/notice-compounders-changes-affect-compounding-march-23-2020